Literature DB >> 20922178

PURLs: Add a fibrate to a statin?

Jody Lounsbery1, Shailendra Prasad, Kate Rowland.   

Abstract

For most patients with diabetes and dyslipidemia, adding a fibrate does not improve cardiovascular outcomes.

Entities:  

Year:  2010        PMID： 20922178      PMCID： PMC3183933     

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


  5 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Effects of combination lipid therapy in type 2 diabetes mellitus.

Authors:  Henry N Ginsberg; Marshall B Elam; Laura C Lovato; John R Crouse; Lawrence A Leiter; Peter Linz; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard H Grimm; Faramarz Ismail-Beigi; J Thomas Bigger; David C Goff; William C Cushman; Denise G Simons-Morton; Robert P Byington
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

3.  Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

Authors:  Hanna Bloomfield Rubins; Sander J Robins; Dorothea Collins; David B Nelson; Marshall B Elam; Ernst J Schaefer; Fred H Faas; James W Anderson
Journal:  Arch Intern Med       Date:  2002 Dec 9-23

4.  Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

Authors:  John B Buse; J Thomas Bigger; Robert P Byington; Lawton S Cooper; William C Cushman; William T Friedewald; Saul Genuth; Hertzel C Gerstein; Henry N Ginsberg; David C Goff; Richard H Grimm; Karen L Margolis; Jeffrey L Probstfield; Denise G Simons-Morton; Mark D Sullivan
Journal:  Am J Cardiol       Date:  2007-04-16       Impact factor: 2.778

5.  Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  Russell Scott; Richard O'Brien; Greg Fulcher; Chris Pardy; Michael D'Emden; Dana Tse; Marja-Riitta Taskinen; Christian Ehnholm; Anthony Keech
Journal:  Diabetes Care       Date:  2008-11-04       Impact factor: 19.112
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.